GNRH1 and ovarian hyperstimulation syndrome: The current proof-of-concept study demonstrates that the hCG dosage can be individualized, and therefore, it seems that OHSS after GnRH agonist administration for final oocyte maturation can be avoided by dosage reduction of the hCG rescue bolus without impacting the chance of achieving and/or maintaining a pregnancy.